Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 69.4%, EPS grew 10.4%, free cash flow grew 288.1% and total debt was flat, each against the same quarter a year earlier.
Follow TARS
Tarsus Pharmaceuticals, Inc. (TARS) P/E ratio
Tarsus Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 20.9× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 16 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.5× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)